KZA 0.00% 8.0¢ kazia therapeutics limited

"We are increasingly also exploring additional patient...

  1. 908 Posts.
    lightbulb Created with Sketch. 101
    "We are increasingly also exploring additional patient populations for which a brain penetrant PI3K/mTOR inhibitor may provide significant advantages over the standard of care".

    Given that the company is already planning for commercialisation, and has been doing marketing research, they are also signalling their intention to expand the potential market.
    Companies selling moonbeams and unicorn poo also hype their products, but we clearly are not in that category.
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.